Silicosis medical therapy

Jump to navigation Jump to search

Silicosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Silicosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Silicosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Silicosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Silicosis medical therapy

CDC on Silicosis medical therapy

Silicosis medical therapy in the news

Blogs on Silicosis medical therapy

Directions to Hospitals Treating Silicosis

Risk calculators and risk factors for Silicosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Silicosis is an irreversible condition with no cure. Treatment options currently focus on alleviating the symptoms and preventing complications.

Medical Therapy

Tamoxifen citrate has been used for the treatment of breast cancer for its selective estrogen receptor modulator action. It also inhibits the production of transforming growth factor-beta (TGF-b) and insulin-like growth factor [2,3]. TGF-b has important roles in the formation of fibrosis such as the modulation of inflammation, wound repair, and immunity by decreasing lymphocyte proliferation and encouraging growth of fibroblasts [4]. These effects have been studied in postoperative adhesions [5], keloid fibroblast proliferation, and reducing collagen production [6,7]. In this study, we aimed to investigate possible effects of tamoxifen on progression, prevention, and treatment of the fibrotic pulmonary silicosis disease considering the anti-fibrotic effect shown in aforementioned studies[1]

References

  1. Yoldas O, Karaca T, Bilgin BC, Yilmaz OH, Simsek GG, Alici IO; et al. (2015). "Tamoxifen citrate: a glimmer of hope for silicosis". J Surg Res. 193 (1): 429–34. doi:10.1016/j.jss.2014.08.013. PMID 25218282.

Template:WH Template:WS